PL3536380T3 - Szybko działające kompozycje insuliny - Google Patents

Szybko działające kompozycje insuliny

Info

Publication number: PL3536380T3
Authority: PL; Poland
Prior art keywords: acting insulin; fast acting; insulin compositions; compositions; fast
Prior art date: 2014-05-08

Application number

PL19161129T

Other languages

English (en)

Inventor

Michael Edward CHRISTE

Thomas Andrew HARDY

Original Assignee

Eli Lilly And Company

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2014-05-08

Filing date

2015-05-04

Publication date

2021-12-27

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53189204&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL3536380(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2015-05-04 Application filed by Eli Lilly And Company filed Critical Eli Lilly And Company

2021-12-27 Publication of PL3536380T3 publication Critical patent/PL3536380T3/pl

Links

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
- A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
- A61K31/558—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes
- A61K31/5585—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes having five-membered rings containing oxygen as the only ring hetero atom, e.g. prostacyclin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Diabetes (AREA)
Bioinformatics & Cheminformatics (AREA)
Endocrinology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Zoology (AREA)
Gastroenterology & Hepatology (AREA)
Immunology (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Obesity (AREA)
Hematology (AREA)
Oil, Petroleum & Natural Gas (AREA)
Inorganic Chemistry (AREA)
Emergency Medicine (AREA)
Dermatology (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)

PL19161129T 2014-05-08 2015-05-04 Szybko działające kompozycje insuliny PL3536380T3 (pl)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
US201461990402P	2014-05-08	2014-05-08
EP15723388.3A EP3140008B1 (en)	2014-05-08	2015-05-04	Rapid-acting insulin compositions
PCT/US2015/029010 WO2015171484A1 (en)	2014-05-08	2015-05-04	Rapid-acting insulin compositions
EP19161129.2A EP3536380B8 (en)	2014-05-08	2015-05-04	Rapid-acting insulin compositions

Publications (1)

Publication Number	Publication Date
PL3536380T3 true PL3536380T3 (pl)	2021-12-27

Family

ID=53189204

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
PL15723388T PL3140008T3 (pl)	2014-05-08	2015-05-04	Szybko działające kompozycje insuliny
PL19161129T PL3536380T3 (pl)	2014-05-08	2015-05-04	Szybko działające kompozycje insuliny

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
PL15723388T PL3140008T3 (pl)	2014-05-08	2015-05-04	Szybko działające kompozycje insuliny

Country Status (36)

Country	Link
US (2)	US9439952B2 (pl)
EP (3)	EP3140008B1 (pl)
JP (1)	JP6050902B2 (pl)
KR (1)	KR101858890B1 (pl)
CN (1)	CN106456717B (pl)
AP (1)	AP2016009525A0 (pl)
AR (1)	AR100155A1 (pl)
AU (1)	AU2015256355B2 (pl)
BR (1)	BR112016024357B1 (pl)
CA (1)	CA2945188C (pl)
CL (1)	CL2016002772A1 (pl)
CY (2)	CY1121669T1 (pl)
DK (2)	DK3536380T3 (pl)
EA (1)	EA031134B1 (pl)
ES (2)	ES2733639T3 (pl)
HR (2)	HRP20190777T1 (pl)
HU (2)	HUE055742T2 (pl)
IL (1)	IL248350B (pl)
JO (1)	JO3624B1 (pl)
LT (2)	LT3536380T (pl)
MA (1)	MA39441A1 (pl)
ME (1)	ME03384B (pl)
MX (1)	MX367521B (pl)
NZ (1)	NZ724919A (pl)
PE (1)	PE20161408A1 (pl)
PH (1)	PH12016502195A1 (pl)
PL (2)	PL3140008T3 (pl)
PT (2)	PT3140008T (pl)
RS (2)	RS58726B1 (pl)
SG (1)	SG11201608424WA (pl)
SI (2)	SI3140008T1 (pl)
TN (1)	TN2016000443A1 (pl)
TR (1)	TR201906843T4 (pl)
TW (1)	TWI685348B (pl)
UA (1)	UA124919C2 (pl)
WO (1)	WO2015171484A1 (pl)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
HUE032284T2 (en)	2008-03-18	2017-09-28	Novo Nordisk As	Protease-stabilized, acylated insulin analogues
EP2919804B1 (fr)	2012-11-13	2018-01-31	Adocia	Formulation à action rapide d'insuline comprenant un composé anionique substitué
US9505737B2 (en)	2013-01-11	2016-11-29	Corsair Pharma, Inc.	Treprostinil derivative compounds and methods of using same
EP3712142B1 (en)	2013-01-11	2022-07-06	Corsair Pharma, Inc.	Prodrugs of treprostinil
US20180221385A1 (en) *	2015-07-28	2018-08-09	Societe De Commercialisation Des Produits De La Recherche Appliquee Socpra Sciences Sante Et	A pharmaceutical preparation for improving absorption and postprandial hypoglycemic action of insulin
JO3749B1 (ar) *	2015-08-27	2021-01-31	Lilly Co Eli	تركيبات إنسولين سريعة المفعول
IL260823B2 (en) *	2016-01-29	2024-08-01	Mannkind Corp	Dry powder inhaler
GB201607918D0 (en)	2016-05-06	2016-06-22	Arecor Ltd	Novel formulations
WO2018058124A1 (en)	2016-09-26	2018-03-29	United Therapeutics Corporation	Treprostinil prodrugs
EP4265296A3 (en)	2016-09-29	2023-12-20	Arecor Limited	Pharmaceutical formulation comprising an insulin compound
ES2886837T3 (es)	2016-12-16	2021-12-21	Novo Nordisk As	Composiciones farmacéuticas que contienen insulina
GB201707187D0 (en)	2017-05-05	2017-06-21	Arecor Ltd	Novel formulations
GB201707189D0 (en)	2017-05-05	2017-06-21	Arecor Ltd	Novel formulations
GB201707188D0 (en)	2017-05-05	2017-06-21	Arecor Ltd	Novel formulations
CA3065308C (en) *	2017-06-01	2022-05-17	Eli Lilly And Company	Rapid-acting insulin compositions
JP7465813B2 (ja)	2018-04-04	2024-04-11	アレコルリミテッド	インスリン化合物の送達のための医療用注入ポンプシステム
EP3773474B1 (en)	2018-04-04	2026-01-07	Arecor Limited	Medical infusion pump system for the delivery of an insulin compound
EP3773473B1 (en)	2018-04-04	2026-07-01	Arecor Limited	MEDICAL INFUSION PUMP SYSTEM FOR ADMINISTRATING AN INSULIN COMPOUND
FR3083985A1 (fr)	2018-07-23	2020-01-24	Adocia	Dispositif pour injecter une solution d'insuline(s)
WO2019243627A1 (fr)	2018-06-23	2019-12-26	Adocia	Dispositif pour injecter une solution d'insuline(s)
CN112739679B (zh)	2018-09-18	2024-03-12	伊莱利利公司	曲前列环素的特丁胺盐
US10799564B1 (en) *	2019-05-06	2020-10-13	Baxter International Inc.	Insulin premix formulation and product, methods of preparing same, and methods of using same
CN114096269B (zh) *	2019-07-12	2024-06-11	诺和诺德股份有限公司	高浓度胰岛素制剂
CN114616225A (zh)	2019-08-23	2022-06-10	联合治疗公司	曲前列环素前药
GB202004814D0 (en)	2020-04-01	2020-05-13	Arecor Ltd	Novel formulations
IL296567A (en)	2020-04-17	2022-11-01	United Therapeutics Corp	Terfostinil for use in the treatment of interstitial lung disease
AU2021289336B2 (en)	2020-06-09	2025-08-28	Mannkind Corporation	Fumaryl diketopiperidine prodrugs of treprostinil
CN115697379A (zh) *	2020-06-30	2023-02-03	江苏恒瑞医药股份有限公司	速效胰岛素组合物及其医药用途
KR102849520B1 (ko)	2020-12-14	2025-08-25	유나이티드 쎄러퓨틱스 코포레이션	트레프로스티닐 프로드러그로 질환을 치료하는 방법
WO2022187352A1 (en)	2021-03-03	2022-09-09	United Therapeutics Corporation	A dry powder composition of trestinil and its prodrug thereof and further comprising comprising (e)-3,6-bis[4-(n-carbonyl-2-propenyl)amidobutyl]-2,5-diketopiperazine (fdkp)
EP4516297A4 (en) *	2022-04-29	2026-02-25	Zhaoke pharmaceutical guangzhou co ltd	Treprostinil Gentle Inhalation Mist
US20240067957A1 (en) *	2022-08-22	2024-02-29	Massachusetts Institute Of Technology	Autocatalytic base editing for rna-responsive translational control

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE2740953A1 (de)	1977-09-12	1979-03-22	Thera Ges Fuer Patente	Verwendung von prostaglandinen zur senkung des blutzuckerspiegels
JPH10251146A (ja) *	1997-03-11	1998-09-22	Toray Ind Inc	糖尿病性神経障害の治療方法
WO2003020201A2 (en) *	2001-08-28	2003-03-13	Eli Lilly And Company	Pre-mixes of glp-1 and basal insulin
WO2003094956A1 (en) *	2002-05-07	2003-11-20	Novo Nordisk A/S	Soluble formulations comprising monomeric insulin and acylated insulin
DE602005020269D1 (de) *	2004-04-12	2010-05-12	United Therapeutics Corp	Verwendung von treprostinil zur behandlung von neuropathischen diabetischen fussgeschwüren
CA2697057A1 (en) *	2007-08-22	2009-02-26	Gilead Colorado, Inc.	Therapy for complications of diabetes
US9387033B2 (en)	2008-08-28	2016-07-12	Roche Diabetes Care, Inc.	Device and method for enhanced subcutaneous insulin absorption
EP2330893A4 (en) *	2008-09-25	2013-01-09	Aradigm Corp	DEEP PULMONARY ADMINISTRATION OF TREPROSTINIL
ES2543705T3 (es)	2009-06-26	2015-08-21	Novo Nordisk A/S	Preparación que contiene insulina, nicotinamida y arginina
KR101701943B1 (ko) *	2009-11-13	2017-02-02	도레이 카부시키가이샤	당뇨병의 치료 또는 예방약
KR20140030125A (ko)	2010-12-14	2014-03-11	노보 노르디스크 에이/에스	인슐린, 니코틴아미드 및 아미노산을 포함하는 제제
BR112014003225A2 (pt) *	2011-08-12	2017-03-01	Ascendis Pharma As	profármacos de treprostinil ligados a veículo
US9381247B2 (en) *	2012-04-16	2016-07-05	Biodel Inc.	Magnesium compositions for modulating the pharmacokinetics and pharmacodynamics of insulin and insulin analogs, and injection site pain
US20150065423A1 (en)	2013-08-30	2015-03-05	Perosphere, Inc.	Rapid acting injectable formulations
WO2015120457A1 (en)	2014-02-10	2015-08-13	Biodel Inc.	Stabilized ultra-rapid-acting insulin formulations

2015
- 2015-04-21 TW TW104112752A patent/TWI685348B/zh active
- 2015-04-21 JO JOP/2015/0079A patent/JO3624B1/ar active
- 2015-04-22 AR ARP150101208A patent/AR100155A1/es not_active Application Discontinuation
- 2015-05-04 JP JP2015563152A patent/JP6050902B2/ja active Active
- 2015-05-04 EA EA201691911A patent/EA031134B1/ru active Protection Beyond IP Right Term
- 2015-05-04 PT PT15723388T patent/PT3140008T/pt unknown
- 2015-05-04 DK DK19161129.2T patent/DK3536380T3/da active
- 2015-05-04 US US14/781,342 patent/US9439952B2/en active Active
- 2015-05-04 MA MA39441A patent/MA39441A1/fr unknown
- 2015-05-04 MX MX2016014643A patent/MX367521B/es active IP Right Grant
- 2015-05-04 LT LTEP19161129.2T patent/LT3536380T/lt unknown
- 2015-05-04 CA CA2945188A patent/CA2945188C/en active Active
- 2015-05-04 RS RS20190582A patent/RS58726B1/sr unknown
- 2015-05-04 SI SI201530716T patent/SI3140008T1/sl unknown
- 2015-05-04 EP EP15723388.3A patent/EP3140008B1/en active Active
- 2015-05-04 PT PT191611292T patent/PT3536380T/pt unknown
- 2015-05-04 AP AP2016009525A patent/AP2016009525A0/en unknown
- 2015-05-04 HU HUE19161129A patent/HUE055742T2/hu unknown
- 2015-05-04 HU HUE15723388 patent/HUE044370T2/hu unknown
- 2015-05-04 PE PE2016002179A patent/PE20161408A1/es unknown
- 2015-05-04 SG SG11201608424WA patent/SG11201608424WA/en unknown
- 2015-05-04 EP EP21183262.1A patent/EP3943155A1/en not_active Withdrawn
- 2015-05-04 UA UAA201611280A patent/UA124919C2/uk unknown
- 2015-05-04 CN CN201580024110.4A patent/CN106456717B/zh active Active
- 2015-05-04 KR KR1020167031043A patent/KR101858890B1/ko active Active
- 2015-05-04 NZ NZ724919A patent/NZ724919A/en unknown
- 2015-05-04 LT LTEP15723388.3T patent/LT3140008T/lt unknown
- 2015-05-04 DK DK15723388.3T patent/DK3140008T3/da active
- 2015-05-04 TR TR2019/06843T patent/TR201906843T4/tr unknown
- 2015-05-04 HR HRP20190777TT patent/HRP20190777T1/hr unknown
- 2015-05-04 PL PL15723388T patent/PL3140008T3/pl unknown
- 2015-05-04 TN TN2016000443A patent/TN2016000443A1/en unknown
- 2015-05-04 ES ES15723388T patent/ES2733639T3/es active Active
- 2015-05-04 BR BR112016024357-9A patent/BR112016024357B1/pt active IP Right Grant
- 2015-05-04 RS RS20211085A patent/RS62291B1/sr unknown
- 2015-05-04 SI SI201531655T patent/SI3536380T1/sl unknown
- 2015-05-04 WO PCT/US2015/029010 patent/WO2015171484A1/en not_active Ceased
- 2015-05-04 AU AU2015256355A patent/AU2015256355B2/en active Active
- 2015-05-04 ES ES19161129T patent/ES2891983T3/es active Active
- 2015-05-04 PL PL19161129T patent/PL3536380T3/pl unknown
- 2015-05-04 ME MEP-2019-126A patent/ME03384B/me unknown
- 2015-05-04 EP EP19161129.2A patent/EP3536380B8/en active Active
2016
- 2016-09-08 US US15/259,101 patent/US10172922B2/en active Active
- 2016-10-13 IL IL248350A patent/IL248350B/en active IP Right Grant
- 2016-11-02 CL CL2016002772A patent/CL2016002772A1/es unknown
- 2016-11-04 PH PH12016502195A patent/PH12016502195A1/en unknown
2019
- 2019-05-31 CY CY20191100581T patent/CY1121669T1/el unknown
2021
- 2021-08-20 CY CY20211100747T patent/CY1124454T1/el unknown
- 2021-09-07 HR HRP20211415TT patent/HRP20211415T1/hr unknown

Also Published As

Publication number	Publication date
PT3536380T (pt)	2021-09-02
RS62291B1 (sr)	2021-09-30
TW201625291A (zh)	2016-07-16
HRP20190777T1 (hr)	2019-08-23
CY1124454T1 (el)	2022-07-22
WO2015171484A1 (en)	2015-11-12
US9439952B2 (en)	2016-09-13
EP3536380A1 (en)	2019-09-11
TR201906843T4 (tr)	2019-05-21
JO3624B1 (ar)	2020-08-27
EA201691911A1 (ru)	2017-02-28
PT3140008T (pt)	2019-06-25
HUE055742T2 (hu)	2021-12-28
TN2016000443A1 (en)	2018-04-04
EP3536380B8 (en)	2021-09-22
RS58726B1 (sr)	2019-06-28
SI3536380T1 (sl)	2021-09-30
ES2733639T3 (es)	2019-12-02
CY1121669T1 (el)	2020-07-31
AR100155A1 (es)	2016-09-14
TWI685348B (zh)	2020-02-21
LT3536380T (lt)	2021-08-10
SG11201608424WA (en)	2016-11-29
IL248350B (en)	2020-03-31
DK3536380T3 (da)	2021-08-02
US20160129087A1 (en)	2016-05-12
JP6050902B2 (ja)	2016-12-21
AP2016009525A0 (en)	2016-10-31
SI3140008T1 (sl)	2019-06-28
AU2015256355A1 (en)	2016-10-27
PH12016502195B1 (en)	2017-02-06
US20160367640A1 (en)	2016-12-22
KR101858890B1 (ko)	2018-05-16
NZ724919A (en)	2018-01-26
MA39441A1 (fr)	2017-06-30
CN106456717A (zh)	2017-02-22
EP3536380B1 (en)	2021-07-07
EA031134B1 (ru)	2018-11-30
MX2016014643A (es)	2017-03-06
KR20160133567A (ko)	2016-11-22
ES2891983T3 (es)	2022-02-01
PL3140008T3 (pl)	2019-09-30
DK3140008T3 (da)	2019-06-24
IL248350A0 (en)	2016-11-30
AU2015256355B2 (en)	2017-09-14
CA2945188A1 (en)	2015-11-12
PH12016502195A1 (en)	2017-02-06
EP3140008A1 (en)	2017-03-15
BR112016024357A2 (pt)	2017-10-10
HRP20211415T1 (hr)	2021-12-10
LT3140008T (lt)	2019-05-27
CA2945188C (en)	2018-12-11
CL2016002772A1 (es)	2017-06-09
PE20161408A1 (es)	2016-12-28
EP3140008B1 (en)	2019-04-17
UA124919C2 (uk)	2021-12-15
CN106456717B (zh)	2020-01-17
BR112016024357B1 (pt)	2022-08-23
US10172922B2 (en)	2019-01-08
EP3943155A1 (en)	2022-01-26
HUE044370T2 (hu)	2019-10-28
JP2016523807A (ja)	2016-08-12
MX367521B (es)	2019-08-26
ME03384B (me)	2020-01-20

Publication	Publication Date	Title
DK3140008T3 (da)	2019-06-24	Hurtigtvirkende insulinsammensætninger
DK3130649T3 (da)	2025-02-03	Haloolefin-baseret sammensætning
DK3233108T3 (da)	2022-04-11	Hurtigtvirkende insulinsammensætninger
DK3215173T3 (da)	2020-03-23	Glycopeptidsammensætninger
BR112016030368A2 (pt)	2018-07-17	composição oftálmica
SMT202400518T1 (it)	2025-01-14	Composizioni anticancro
FR3024363B1 (fr)	2018-08-10	Composition thermogelifiable
DK3198111T3 (da)	2020-08-03	Forbedret prop
LT3226843T (lt)	2021-08-10	Priešvėžinės kompozicijos
LT3226842T (lt)	2021-03-25	Priešvėžinės kompozicijos
DK3171700T3 (da)	2020-12-14	Infusionsanlæg
DK3129007T3 (da)	2020-11-02	Vaccinesammensætninger
CL2017000639A1 (es)	2018-01-26	Composición
PT3200772T (pt)	2022-10-19	Composições farmacêuticas compreendendo alpelisib
HUE070090T2 (hu)	2025-05-28	Összetétel
DK3200827T3 (da)	2020-10-12	Sammensætninger
DK3148513T3 (da)	2020-05-25	Ceritinib-formulering
DK3217964T3 (da)	2019-11-25	Sammensætning
DK3193856T3 (da)	2021-09-06	Formulering
DK3089740T3 (da)	2020-08-03	Farmaceutisk sammensætning
FR3019552B1 (fr)	2016-04-01	Composition filmogene
DK3441063T3 (da)	2021-08-30	Flydende thioureylensammensætninger
DK3001076T3 (da)	2019-06-24	Tilbageløbsforhindrer
DK3119380T3 (da)	2019-07-01	Sammensætning omfattende biprodukter
UA28872S (uk)	2015-02-10	Шприц